{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fa16z.simplecast.com%2Fepisodes%2Ferooms-law-kxqllHa1","width":444,"version":"1.0","type":"rich","title":"Journal Club: Revisiting Eroom's Law","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/a190663c-ef4c-4448-9057-0e0eff19916c/ae34bfa3-f1e1-455a-98af-9e8c24ec727c/copy-of-untitled-design-5.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/0f0bc4a2-f7e6-409c-9d2e-deb2c75056ab\" height=\"200\" width=\"100%\" title=\"Journal Club: Revisiting Eroom&apos;s Law\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"With @jorgecondebio @vijaypande and @lr_bio\n\nOn this special holiday weekend edition of the a16z bio Journal Club we discuss a recent opinion article suggesting the end of Eroom’s Law—the decades long trend in biopharma R&D towards higher and higher costs per new drug—and our take on the big trends in this space.\n"}